Biophytis Shares Drop Over 90% in a Year, Reaching a Critical Threshold
This Thursday morning, Biophytis shows a rebound of 3.45% at €0.0300, after having reached the same floor level the previous day. This temporary surge does not obscure the extent of the erosion suffered by the French biotech, whose stock has lost more than 90% of its value in twelve months. During the session, the CAC 40 is down by 1.64%, in a generally declining Paris market.
Critical Support Level Reached
Biophytis' stock price is now hovering at its support threshold of €0.03, which also represents the lower boundary of the Bollinger Bands. This level is critical: if broken, there would be no immediate technical plateau to hinder further decline. The weekly performance of -33.18% and quarterly of -61.98% illustrate the severity of the correction movement over the past months. The RSI, an indicator measuring buying and selling momentum, has dropped to 9, an extremely low level indicating a pronounced oversold condition. Historically, such a low RSI could precede temporary technical rebounds, but it is by no means a signal of a lasting turnaround. The stock remains significantly distant from its 50-day (€0.05) and 200-day (€0.11) moving averages, confirming its entrenched downward trend.
High Volatility and Negative Beta
Biophytis' monthly volatility reaches 38.02, a high level reflecting wide and unpredictable price fluctuations, typical of micro-cap companies in the biotech sector. This parameter should be considered in light of the stock’s negative beta, established at -0.69. This value indicates that the stock tends to move in the opposite direction of the market, which is an atypical behavior within the Paris stock exchange. During this morning's session, the SBF 120 is down 1.65%, in a context of a general decline in European indices. Thus, Biophytis' modest rebound occurs in a market downturn, consistent with the inverse correlation reflected by its beta. The nearest resistance threshold is at €0.06, double the current price, a considerable gap that highlights the distance separating the stock from any significant recovery zone. At this stage, the company's market capitalization has been reduced to a marginal level, and trading on the stock remains confined to volumes characteristic of very small-cap values.
